Literature DB >> 21041507

Polymyxin-resistant clinical isolates of Escherichia coli.

Carl Urban1, Hemavarna Tiruvury, Noriel Mariano, Rita Colon-Urban, James J Rahal.   

Abstract

A surveillance study to identify patients from the community with Escherichia coli resistant to broad-spectrum cephalosporins discovered two isolates that were also resistant to polymyxin B and colistin. One isolate from a patient in the community and a second from a patient who received multiple courses of polymyxin B also possessed a CTX-M-15 enzyme. Resistance to cationic peptides in E. coli is unusual, and testing for susceptibility to these agents should be performed.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21041507      PMCID： PMC3019679          DOI： 10.1128/AAC.01088-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Origin of lipid A species modified with 4-amino-4-deoxy-L-arabinose in polymyxin-resistant mutants of Escherichia coli. An aminotransferase (ArnB) that generates UDP-4-deoxyl-L-arabinose.

Authors:  Steven D Breazeale; Anthony A Ribeiro; Christian R H Raetz
Journal:  J Biol Chem       Date:  2003-04-18       Impact factor: 5.157

Review 2.  Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?

Authors:  Kim A Brogden
Journal:  Nat Rev Microbiol       Date:  2005-03       Impact factor: 60.633

Review 3.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.

Authors:  Helen W Boucher; George H Talbot; John S Bradley; John E Edwards; David Gilbert; Louis B Rice; Michael Scheld; Brad Spellberg; John Bartlett
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

4.  Successive emergence of Enterobacter aerogenes strains resistant to imipenem and colistin in a patient.

Authors:  Aurélie Thiolas; Claude Bollet; Bernard La Scola; Didier Raoult; Jean-Marie Pagès
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States.

Authors:  James R Johnson; Brian Johnston; Connie Clabots; Michael A Kuskowski; Mariana Castanheira
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

6.  Identification of CTX-M beta-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities.

Authors:  Carl Urban; Noriel Mariano; Patricia A Bradford; Margareta Tuckman; Sorana Segal-Maurer; Wehbeh Wehbeh; Louise Grenner; Rita Colon-Urban; Brian Johnston; James R Johnson; James J Rahal
Journal:  Diagn Microbiol Infect Dis       Date:  2010-04       Impact factor: 2.803

7.  Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster.

Authors:  Anastasia Antoniadou; Flora Kontopidou; Garifalia Poulakou; Evangelos Koratzanis; Irene Galani; Evangelos Papadomichelakis; Petros Kopterides; Maria Souli; Apostolos Armaganidis; Helen Giamarellou
Journal:  J Antimicrob Chemother       Date:  2007-02-16       Impact factor: 5.790

8.  In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008.

Authors:  A Walkty; M DeCorby; K Nichol; J A Karlowsky; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

9.  Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).

Authors:  A C Gales; R N Jones; H S Sader
Journal:  Clin Microbiol Infect       Date:  2006-04       Impact factor: 8.067

Review 10.  Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature.

Authors:  Azza Elemam; Joseph Rahimian; William Mandell
Journal:  Clin Infect Dis       Date:  2009-07-15       Impact factor: 9.079
View more
  7 in total

1.  A CRISPR-Cas system enhances envelope integrity mediating antibiotic resistance and inflammasome evasion.

Authors:  Timothy R Sampson; Brooke A Napier; Max R Schroeder; Rogier Louwen; Jinshi Zhao; Chui-Yoke Chin; Hannah K Ratner; Anna C Llewellyn; Crystal L Jones; Hamed Laroui; Didier Merlin; Pei Zhou; Hubert P Endtz; David S Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

2.  NDM-1-producing Klebsiella pneumoniae resistant to colistin in a French community patient without history of foreign travel.

Authors:  Corinne Arpin; Patrick Noury; Delphine Boraud; Laure Coulange; Alain Manetti; Catherine André; Fatima M'Zali; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

3.  Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli.

Authors:  Janet A Hindler; Romney M Humphries
Journal:  J Clin Microbiol       Date:  2013-03-13       Impact factor: 5.948

4.  Multicenter prospective study on the prevalence of colistin resistance in Escherichia coli: relevance of mcr-1-positive clinical isolates in Lombardy, Northern Italy.

Authors:  Luigi Principe; Aurora Piazza; Carola Mauri; Adriano Anesi; Silvia Bracco; Gioconda Brigante; Erminia Casari; Carlo Agrappi; Mariasofia Caltagirone; Federica Novazzi; Roberta Migliavacca; Laura Pagani; Francesco Luzzaro
Journal:  Infect Drug Resist       Date:  2018-03-09       Impact factor: 4.003

5.  Biodegradable nanocarriers coated with polymyxin B: Evaluation of leishmanicidal and antibacterial potential.

Authors:  Juliana Souza Ribeiro Costa; Marília Medeiros; Edite Harumi Yamashiro-Kanashiro; Mussya Cisotto Rocha; Paulo Cesar Cotrim; Marco Antonio Stephano; Marcelo Lancellotti; Guilherme Diniz Tavares; Laura Oliveira-Nascimento
Journal:  PLoS Negl Trop Dis       Date:  2019-05-01

6.  Low-dose polymyxin: an option for therapy of Gram-negative sepsis.

Authors:  Stephan Harm; Franz Gabor; Jens Hartmann
Journal:  Innate Immun       Date:  2016-03-17       Impact factor: 2.680

7.  Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii.

Authors:  Thien B Tran; Soon-Ee Cheah; Heidi H Yu; Phillip J Bergen; Roger L Nation; Darren J Creek; Anthony Purcell; Alan Forrest; Yohei Doi; Jiangning Song; Tony Velkov; Jian Li
Journal:  J Antibiot (Tokyo)       Date:  2015-12-16       Impact factor: 2.649
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.